Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Colorcon
Merck
Moodys
Express Scripts

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD8871

See Plans and Pricing

« Back to Dashboard

What is the drug development status for AZD8871?

AZD8871 is an investigational drug.

There have been 5 clinical trials for AZD8871. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are AstraZeneca, Parexel, and Covance.

There are three US patents protecting this investigational drug and sixty-five international patents.

Recent Clinical Trials for AZD8871
TitleSponsorPhase
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.ParexelPhase 2
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.AstraZenecaPhase 2
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese SubjectsCovancePhase 1

See all AZD8871 clinical trials

Clinical Trial Summary for AZD8871

Top disease conditions for AZD8871
Top clinical trial sponsors for AZD8871

See all AZD8871 clinical trials

US Patents for AZD8871

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD8871   Start Trial Cyclohexylamine derivatives having .beta.2 adrenergic agonist and M3 muscarinic antagonist activities ALMIRALL, S.A. (Barcelona, ES)   Start Trial
AZD8871   Start Trial Cyclohexylamine derivatives having .beta.2 adrenergic agonist and M3 muscarinic antagonist activities Almirall, S.A. (Barcelona, ES)   Start Trial
AZD8871   Start Trial Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and .beta.2 adrenergic receptor agonist activities Almirall, S.A. (Barcelona, ES)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD8871

Drugname Country Document Number Estimated Expiration Related US Patent
AZD8871 Argentina 088828 2031-11-11   Start Trial
AZD8871 Australia 2012333986 2031-11-11   Start Trial
AZD8871 Brazil 112014010598 2031-11-11   Start Trial
AZD8871 Canada 2849868 2031-11-11   Start Trial
AZD8871 Chile 2014001018 2031-11-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Johnson and Johnson
Harvard Business School
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.